FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 317:209-213 July 23, 1987 Number 4 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Penicillamine is known to be effective therapy for Wilson's disease. However, the clinical consequences of the abrupt and permanent withdrawal of penicillamine have not been investigated. We studied 11 patients who stopped their own treatment after having been treated successfully with penicillamine (1 to 2 g per day) for periods of 3 to 19 years. Eight died of hepatic decompensation or fulminant hepatitis after an average survival of only 2.6 years. In another 13 patients, penicillamine was discontinued by the physician because of serious adverse reactions. In these patients, penicillamine was replaced with trientine (1 to 1.5 g per day), a newer chelating agent. All but one of these patients (who was killed accidentally) are alive at this writing, from 2 to 15 years later. Our observations suggest that discontinuation of penicillamine in patients with Wilson's disease results in rapid clinical deterioration, which is often fatal. The replacement of penicillamine with trientine appears to prevent this adverse clinical course.

This article has been cited by other articles:

• (1998). Proceedings of the British Toxicology Society Annual Congress University of Surrey, Guildford 19 - 22 April 1998. Hum Exp Toxicol 17: 469-534  
• Jones, E A, Weissenborn, K (1997). Neurology and the liver. J. Neurol. Neurosurg. Psychiatry 63: 279-293 [Full Text]  
• Roth, K.S. (1988). Diagnosis of Renal Tubular Transport Disorders: A Guide for the Clinician. CLIN PEDIATR 27: 463-470